Lung Cancer Market, By Type (Small cell lung cancer (SCLC), Non-small cell lung cancer (NSCLC)), By Treatment (Chemotherapy, Laser Therapy, Radiotherapy, Immunotherapy, Surgery, and Others), By End-Users (Hospitals, Clinics, Cancer Research Centers, Laboratories, and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2032

Report Code: PMI497422 | Publish Date: May 2023 | No. of Pages: 170

Lung Cancer Market Overview

When cancer starts in lungs is called as Lung Cancer . Cancer begin in lungs and spread into lymph nodes and other organs like brain. In metastases cancer is spread from one organ to another. Tobacco, cigarette smoking are main causes of lung cancer. Chest pain, wheezing, coughing, weight loss, feeling tired, shortness of breath are some symptoms of lung cancer. Individual with lung cancer experience shortness of breath in which cancer grows by blocking airways, fluid accumulate around the lungs, coughing with blood, etc. Loss of appetite, shortness of breath, chest pain, coughing up blood, weakness, weight loss are first signs of lung cancer. Five year survival rate for non-small cell lung cancer is 26%, five year survival rate for all types of lung cancer in people is 22%. Individual who smoke cigarette are 15-30 times more at risk to get lung cancer or die due to lung cancer. Lung cancer has become the leading cause of death by cancer, which has made almost 25% of all cancer deaths. Lung cancer spreads rapidly due to its aggressiveness. Early diagnosis and treatment helps in improving chances of living for people with lung cancer for more than five years. Mostly lung cancer spreads or metastasizes in brain, liver, adrenal glands or bones. Lung cancer stars in bronchioles, alveoli, and cell lining bronchi. Lung cancer causes pain and discomfort when tumor starts growing larger. Stage I lung cancer can be curable if treated early by radiation therapy or chemotherapy. Fully cure lung cancer is difficult in patients having more advanced tumor. Lung cancer is removed by lobectomy and bilobectomy. In bilobectomy two lobes are removed. Lung cancer is treated by targeted therapy, radiation therapy, chemotherapy, and by surgery. Individual with SCLC (small lung cancer) are treated with chemotherapy and radiation therapy. Adenocarcinomas has 261 days of median doubling time, small cell carcinomas and large cell carcinomas has 70 days of median doubling time, and squamous cell carcinomas has 70 days of median doubling time. Rise in cigarette smoking, incidence of cancer diseases has enhanced the growth of lung cancer market.

Attributes

Details

Lung Cancer Market Value (2022)

US$ 26.5Bn

Lung Cancer Market Projected Value (2032)

US$ 175.9Bn

Lung Cancer Market CAGR (2022 – 2032)

18.5%

Lung Cancer Market Dynamics

                          Rise in cigarette smoking, cancer disease and rate of urbanization

Rise in cigarette smoking, cancer disease and rate of urbanization is one of the leading factors for the Lung Cancer Market growth. Urbanization has given rise in consumption of western food, unhealthy diet, unhealthy lifestyle, use of alcohol intake, cigarette smoking, has become a fashion trend. Cigarette smoking has become the major factor in developing lung cancer. In U.S. around 80% to 90% lung cancer deaths are caused by cigarette smoking. Tobacco has also become the leading cause of lung cancer as it contains more than 7,000 chemicals. Rise in cigarette smoking has given rise in lung cancer. Lung cancer mortality rates has become higher in urban areas than rural areas because of unhealthy lifestyle, rapid industrialization which has given rise in air pollution, personal behavior, increased use of cigarette smoking, and occupational hazards. Smoking has become major risk factor in cause of lung cancer. Urbanization has given rise in air pollution due to industrialization and rising use of vehicles. In 2016, study in European region has determined that about 5% to 7% of lung cancer was observed in people with no smokers and ex-smokers were attributable to higher level of air pollution as expressed by nitrogen dioxide and road bearing heavy traffic. For instance, in June 2016, difference in lung cancer mortality between city and rural areas were observed in Madrid region and the study determined that most urbanized areas of Madrid region were characterized by higher lung cancer mortality rate. Smoking prevalence from 1985 to 2000 was very high in urban areas and thus it was increased with rapid urbanization. For instance, in 2016, (NIH), the relationship between cancer incidence and urbanization in Iran were conducted by using Quantile Regression. Data obtained by Ministry of Health & Medical Education and relationship between urbanization and cancer morbidity was investigated by quantile regression and determined that lung cancer, pancreas, prostate, colorectal and breast cancers increasing with rate of urbanization. 95th percentile for lung cancer, 90th percentile was maximum increase rate of breast cancer, 95th percentile was of prostate cancer, 75th percentile was of colorectal cancer, and 10th percentile for pancreas cancer. According to the results, it was determined that there was significant impact of rising urbanization on cancer morbidity due to risk factors like more pollution in urban areas, poor nutrition food, lack of exercise, smoking, alcohol intake, etc. According to data published by United Nations in 2018, about 55% of the world’s population resided in urban areas, and it is projected that this percentage will increase over the forecast period. However, the growth cigarette smoking, cancer disease and population in urban areas boosts the demand for lung cancer market.

Restrains:

However, expensive treatments like radiation therapy, immunotherapy, chemotherapy, hospitalization, diagnosis, monthly repeated rounds therapy which cost more may somewhat restrain the lung cancer market growth.

Access Crucial Insights at a Fraction of the Cost | Request Your Discount

Lung Cancer Market Segmentation

 

Lung Cancer Market is segmented based on type, treatment, end-users and region.

Type Insight

On the basis of Type Lung Cancer Market is segmented into Small cell lung cancer (SCLC), Non-small cell lung cancer (NSCLC). Small cell lung cancer (SCLC) has dominated the target market due to its faster spread and growth than non-small lung cancer (NSCLC).

Treatment Insights

On the basis of Treatment Lung Cancer Market is segmented into Chemotherapy, Laser Therapy, Radiotherapy, Immunotherapy, Surgery, and Others. Radiation Therapy has dominated the target market as it is less invasive and having quicker recovery time.

End-Users Insights

On the basis of End-Users Lung Cancer Market is segmented into Hospitals, Clinics, Cancer Research Centers, Laboratories, and Others. Hospitals has dominated the target market because it deals with complete diagnosis and treatment by providing all facilities.

Regional Insights:

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

On region the Lung Cancer Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market is estimated to witness a significantly high revenue share over the forecast period, owing to growing population, especially in countries such as Europe and Asia Pacific, and technological advancements. Moreover, rising prevalence of cancer disease, unhealthy diet, sedentary lifestyle, high disposable income, is anticipated to increase demand for Lung Cancer in the region.

Reduce costs by up to 30% with a custom report tailored to your specific needs | Request Customized Report

Report Scope:

Attribute

Details

Base year for estimation

2022

Forecast period

2022 – 2032

Market representation

Revenue in USD Billion & CAGR from 2022 to 2032

Market Segmentation

By Type - Small cell lung cancer (SCLC), Non-small cell lung cancer (NSCLC)

By Treatment - Chemotherapy, Laser Therapy, Radiotherapy, Immunotherapy, Surgery, and others

By End-Users - Hospitals, Clinics, Cancer Research Centers, Laboratories, and others

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2022 to 2032. For the purpose of this study, has segmented the Lung Cancer Market report based on type, treatment, end-users and region:

Lung Cancer Market, By Type:

  • Small cell lung cancer (SCLC)
  • Non-small cell lung cancer (NSCLC)

Lung Cancer Market, By Treatment:

  • Chemotherapy
  • Laser Therapy
  • Radiotherapy
  • Immunotherapy
  • Surgery
  • Others

Lung Cancer Market, By End-Users:

  • Hospitals
  • Clinics
  • Cancer Research Centers
  • Laboratories
  • Others

Lung Cancer Market, By Region:

      • North America
          • U.S.
          • Canada
      • Europe
          • Germany
          • UK
          • France
          • Russia
          • Italy
          • Rest of Europe
      • Asia Pacific
          • China
          • India
          • Japan
          • South Korea
          • Rest of Asia Pacific
      • Latin America
          • Brazil
          • Mexico
          • Rest of Latin America
      • Middle East & Africa
          • GCC
          • Israel
          • South Africa
          • Rest of Middle East & Africa

Lung Cancer Market Key Players

The key players operating the Lung Cancer Market includes,

  1. AstraZeneca Plc.

AstraZeneca is the British Swedish multinational pharmaceutical and biotechnology company. AstraZeneca is leading a revolution in oncology for redefining cancer care for millions of American living with cancer. AstraZeneca offers products for major diseases which includes, gastrointestinal infection, cardiovascular, neuroscience, oncology, respiratory & inflammation, etc.

  1. Hoffman La Roche

Hoffman La Roche is a Swiss multinational healthcare company that develops drugs & diagnostics in treating major diseases. Hoffman La Roche provides a medicinal treatment for cancer, infectious diseases, central nervous system disorder, respiratory diseases, and auto-immune diseases.

  1. Eli Lilly and Company

Eli Lilly is an American Pharmaceutical Company which is headquartered in Indianapolis, Indiana. Eli Lilly provides high quality products in healthcare, best for clinical depression drugs, and has focused on creating new medicine on cancer.

  1. Pfizer Inc.

Pfizer is an American multinational pharmaceutical and biotechnology corporation which is headquartered in Manhattan, New York City. Pfizer is the manufacturer of drug products, active pharmaceutical ingredients (API), and medical devices in various diseases.

  1. Merck & Co.

Merck & Co., is an American multinational pharmaceutical company which is headquartered in Rahway, New Jersey. Merck & Co., is a global healthcare company delivering innovative health solutions like medicines, biologic therapies, vaccines, and animal health products.

  1. Amgen Inc.,

Amgen is an American multinational biopharmaceutical company which is headquartered in Thousand Oaks, California. Amgen is a world-wide leader in biologics manufacturing. Amgen is pioneer in using living cells for making biologic medicines used for treating leukemia, headache, arthritis, anemia and others.

  1. Novartis AG,

Novartis AG, is a Swiss-American multinational pharmaceutical company in Basel, Cambridge and Switzerland. Novartis is the leader in field of generic drugs. Novartis provides, innovative drugs, oncology products, pharmaceutical products, etc.

  1. Johnson & Johnson

Johnson & Johnson, is an American multinational company. Johnson & Johnson is the largest and widely based healthcare company in world. Johnson & Johnson develops pharmaceutical products, medical devices, consumer packaged goods.

  1. Teva Pharmaceuticals Industries Ltd.

Teva Pharmaceuticals is an Israeli multinational pharmaceutical company which headquartered in Tel Aviv Israel. Teva Pharmaceuticals is the global leader in biopharmaceuticals and generic products.

  1. Bristol-Myers Squibb Company

Bristol-Myers Squibb Company is an American multinational pharmaceutical company which is headquartered in New York City. Bristol-Myers Squibb Company is the manufacturer in biologics and pharmaceuticals which includes, cancer, cardiovascular disease, HIV AIDS, diabetes, psychiatric disorders, rheumatoid arthritis and hepatitis.

Recent Development:

  • In June 2022, Novartis has received European Commission approval for ‘Tabrecta’ for treating METex14 skipping advanced NSCLC (non-small cell lung cancer). Newly launched ‘Tabrecta’ has provided new targeted therapy option for patients in Europe with advanced non-small cell lung cancer (NSCLC) which harbor alterations leading to MET exon 14 (METex14) skipping. Tabrecta has become monotherapy for treating adults with advanced NSCLC (non-small cell lung cancer).
  • In September 2022, Amgen has announced result in detail from Phase 3 CodeBreak 200 trial which has showed once daily oral LUMAKRAS/LUMYKRAS that has led to significantly higher objective response rate (ORR – key secondary endpoint) in patients with KRAS G12C-mutated NSCLC (non-small cell lung cancer) compared with intravenous chemotherapy, docetaxel.

Lung Cancer Market Company Profile

  • Novartis AG*
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • AstraZeneca
  • Hoffman La Roche
  • Eli Lilly and Company
  • Pfizer Inc.
  • Merck & Co.
  • Amgen Inc.*
  • Johnson & Johnson
  • Teva Pharmaceuticals Industries Ltd.
  • Bristol-Myers Squibb Company. 

“*” marked represents similar segmentation in other categories in the respective section.

Lung Cancer Market Table of Contents

  1. Research Objective and Assumption
    • Preface
    • Research Objectives
    • Study Scope
    • Years Considered for the study
    • Assumptions
    • Abbreviations
  2. Research Methodology
    • Research data
    • Primary Data
      • Primary Interviews
      • Primary Breakdown
      • Key data from Primary Sources
      • Key Thickness Insights
    • Secondary Data
      • Major Secondary Sources
      • Secondary Sources
    • Market Estimation
    • Top-Down Approach
      • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
    • Bottom-Up Approach
      • Approach for estimating market share by Bottom-up Analysis (Demand Side)
    • Market Breakdown and Data Triangulation
    • Research Assumptions
  3. Market Purview
    • Executive Summary
    • Key Findings—Global Outlook for medical carts Strategies
      • Key Questions this Study will Answer
      • Market Snippet, By Type
      • Market Snippet, By Treatment
      • Market Snippet, By End-Users
      • Market Snippet, By Region
    • Opportunity Map Analysis
    • Executive Summary—3 Big Predictions
  4. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restrains
      • Market Opportunities
      • Market Trends
    • DR Impact Analysis
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Opportunity Orbit
    • Market Investment Feasibility Index
    • Macroeconomic Factor Analysis
  5. Lung Cancer  Market, By Type
    • Overview
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
      • Y-o-Y Growth Analysis (%), 2022 – 2032
      • Segment Trends
    • Small cell lung cancer (SCLC)
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Non-small cell lung cancer (NSCLC)
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
  6. Lung Cancer  Market, By Treatment, 2022 – 2032, (US$ Bn)
    • Overview                                      
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
      • Y-o-Y Growth Analysis (%), 2022 – 2032
      • Segment Trends
    • Chemotherapy
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Laser Therapy
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Radiotherapy
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Immunotherapy
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Surgery
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Others
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
  1. Lung Cancer  Market, By End-Users, 2022 – 2032, (US$ Bn)
    • Overview                                      
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
      • Y-o-Y Growth Analysis (%), 2022 – 2032
      • Segment Trends
    • Hospitals
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Clinics
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Cancer Research Centers
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Laboratories
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
    • Others
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2022 – 2032
  2. Lung Cancer  Market, By Region, 2022 – 2032, (US$ Bn)
    • Overview
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2022 – 2032
      • Y-o-Y Growth Analysis (%), 2022 – 2032
      • Regional Trends
    • North America
      • Market Size and Forecast (US$ Bn), By Type, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Treatment, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By End-Users, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast (US$ Bn), By Type, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Treatment, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By End-Users, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
        • UK
        • France
        • Germany
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast (US$ Bn), By Type, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Treatment, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By End-Users, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
        • India
        • Japan
        • South Korea
        • China
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast (US$ Bn), By Type, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Treatment, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By End-Users, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • Market Size and Forecast (US$ Bn), By Type, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Treatment, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By End-Users, 2022 – 2032
      • Market Size and Forecast (US$ Bn), By Country, 2022 – 2032
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East
  2. Competitive Landscape
    • Heat Map Analysis
    • Market Presence and Specificity Analysis
  3. Company Profiles
  • AstraZeneca
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Hoffman La Roche
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Eli Lilly and Company
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Merck & Co.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Amgen Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Novartis AG
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Johnson & Johnson
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Teva Pharmaceuticals Industries Ltd.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Bristol-Myers Squibb Company
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  1. The Last Word
    • Future Impact
    • About Us
    • Contact

FAQs

The Lung Cancer Market is segmented into type, treatment, end-users and region.

Lung Cancer Market is driven by factors like rise in cigarette smoking, cancer diseases, and rate of urbanization.

By region, the Lung Cancer market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market is estimated to witness a significantly high revenue share over the forecast period, owing to growing population, especially in countries such as Europe and Asia Pacific, and technological advancements.

The key players operating the Lung Cancer Market includes, AstraZeneca, Hoffman La Roche, Eli Lilly and Company, Pfizer Inc., Merck & Co., Amgen Inc., Novartis AG, Johnson & Johnson, Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb Company.